Drugs / ICM-203
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05454566 | Nov 2026 → May 2027 expected | osteoarthritis, knee | ICM Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04875754 | Mar 2022 → Mar 2026 overdue | osteoarthritis, knee | ICM Biotech Australia Pty Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICM-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05454566 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a recombinant adeno-associated viral (AAV) vector” NCT04875754 ↗ |
| Route | Other | “Intra-articular injection” NCT04875754 ↗ |